Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to...

Area of Science:

• Hematology
• Infectious Diseases
• Oncology

Background:

• The COVID-19 pandemic disproportionately affected individuals with hematological malignancies due to compromised immunity.
• Standard interventions for COVID-19 may offer reduced efficacy in this vulnerable patient group.

Purpose of the Study:

• To analyze COVID-19 outcomes in patients with hematological malignancies using data from the EPICOVIDEHA registry.
• To identify trends in critical infections, mortality, and survival factors over the first three years of the pandemic.

Main Methods:

• Data were collected from January 2020 to December 2022 via the EPICOVIDEHA registry (NCT04733729).
• The study included 8767 COVID-19 cases from 152 centers across 41 countries.
• Analysis focused on mortality rates, critical infections, and factors influencing survival.

Main Results:

• Overall mortality decreased from 29% to 4% between 2020 and 2022.
• Vaccination (1-2 or 3+ doses) and contracting COVID-19 in 2022 were associated with improved survival.
• Hospitalization, particularly ICU admission, remained linked to higher mortality.

Conclusions:

• Despite improvements, hematological malignancy patients remain at high risk for severe COVID-19.
• Vaccination and timely 2022 exposure are crucial for better survival outcomes.
• Continued monitoring and targeted interventions are vital for this population.